# Study of JS001 in Participants With Advanced Solid Tumors

> **NCT02857166** · PHASE1 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **BIOLOGICAL:** humanized anti-PD-1 monoclonal antibody toripalimab

## Key facts

- **NCT ID:** NCT02857166
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2017-09
- **Final completion:** 2018-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02857166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02857166, "Study of JS001 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02857166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*